Joy brings us together
KIRIN

KIRIN HOLDINGS COMPANY, LIMITED

February 14, 2025

SUMMARY OF CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 (UNDER IFRS) (UNAUDITED)

(English Translation)

Fiscal year ended December 31, 2024

KIRIN HOLDINGS COMPANY, LIMITED

NAKANO CENTRAL PARK SOUTH, 10-2, Nakano 4-chome, Nakano-ku, Tokyo, Japan (URL https://www.kirinholdings.com/en/)

Code No.:	2503
Shares Listed:	Tokyo
Representative:	Mr. Takeshi Minakata, President and COO
For further information, please contact:	Mr. Hidefumi Matsuo, General Manager of Finance Department Telephone: +81-3-6837-7015 from overseas

Scheduled date of general meeting of shareholders held:	March 28, 2025
Commencement date of dividend distribution scheduled:	March 31, 2025
Submission date of securities report scheduled:	March 28, 2025
Preparation of supplementary documents to the financial results:	Yes
Holding of financial results presentation (for institutional investors and analysts):	Yes

1. Consolidated business results and financial position for the current fiscal year (January 1, 2024 - December 31, 2024)

[Unit: Japanese yen (¥)]

(1) Results of operations:

(Amounts are rounded to the nearest ¥1 million)

(Percentage change compares current results with those of the same period of the previous year)

	Revenue (¥ millions)	Percentage change (%)	Normalized operating profit (¥ millions)	Percentage change (%)	Profit before tax (¥ millions)	Percentage change (%)
Fiscal year ended						
December 31, 2024	2,338,385	9.6	210,968	4.7	139,721	(29.1)
December 31, 2023	2,134,393	7.3	201,495	5.4	197,049	3.0

	Profit (¥ millions)	Percentage change (%)	Profit attributable to owners of the Company (¥ millions)	Percentage change (%)	Total comprehensive income (¥ millions)	Percentage change (%)
Fiscal year ended						
December 31, 2024	85,811	(43.0)	58,214	(48.3)	158,187	(39.6)
December 31, 2023	150,438	4.6	112,697	1.5	261,801	19.1

	Basic earnings per share (¥)	Diluted earnings per share (¥)	Ratio of profit to equity attributable to owners of the Company (%)	Ratio of profit before tax to total assets (%)	Ratio of normalized operating profit to revenue (%)
Fiscal year ended					
December 31, 2024	71.87	71.86	5.0	4.5	9.0
December 31, 2023	139.16	139.15	10.7	7.3	9.4

Reference: Share of profit of equity-accounted investees	Fiscal year ended December 31, 2024	¥37,035 million
	Fiscal year ended December 31, 2023	¥32,773 million

Operating profit	Fiscal year ended December 31, 2024	¥125,340 million	(16.6%)
	Fiscal year ended December 31, 2023	¥150,294 million	29.5%
Ratio of operating profit to revenue	Fiscal year ended December 31, 2024	5.4%	
	Fiscal year ended December 31, 2023	7.0%	

* Normalized operating profit is a profit indicator for measuring recurring performance which is calculated by deducting cost of sales and selling, general and administrative expenses from revenue.

(2) Financial position:

	Total assets (¥ millions)	Total equity (¥ millions)	Equity attributable to owners of the Company (¥ millions)	Equity ratio attributable to owners of the Company (%)	Equity per share attributable to owners of the Company (¥)
As of					
December 31, 2024	3,354,159	1,533,714	1,181,525	35.2	1,458.68
December 31, 2023	2,869,585	1,425,838	1,132,581	39.5	1,398.47

(3) Cash flows:

	Cash flows from operating activities (¥ millions)	Cash flows from investing activities (¥ millions)	Cash flows from financing activities (¥ millions)	Cash and cash equivalents at end of year (¥ millions)
Fiscal year ended December 31, 2024	242,844	(329,375)	58,125	118,617
Fiscal year ended December 31, 2023	203,206	(226,091)	35,909	131,399

2. Dividends

	Annual dividends				
	First quarter (¥)	Second quarter (¥)	Third quarter (¥)	Year-end (¥)	Total (¥)
Fiscal year ended December 31, 2023	—	34.50	—	36.50	71.00
Fiscal year ended December 31, 2024	—	35.50	—	35.50	71.00
Fiscal year ending December 31, 2025 (Forecast)	—	37.00	—	37.00	74.00

	Total amount of dividends (¥ millions)	Dividend pay-out ratio (%)	Ratio of dividends to equity attributable to owners of the Company (%)
Fiscal year ended December 31, 2023	57,637	51.0	5.4
Fiscal year ended December 31, 2024	57,635	98.8	5.0
Fiscal year ending December 31, 2025 (Forecast)		40.0	

3. Forecast consolidated business results for the next fiscal year (January 1, 2025 - December 31, 2025)

(Percentage change compares forecast results with actual results of the previous year)

	Revenue (¥ millions)	Percentage change (%)	Normalized operating profit (¥ millions)	Percentage change (%)	Profit before tax (¥ millions)	Percentage change (%)
Fiscal year ending December 31, 2025	2,440,000	4.3	212,000	0.5	230,000	64.6

	Profit (¥ millions)	Percentage change (%)	Profit attributable to owners of the Company (¥ millions)	Percentage change (%)	Basic earnings per share (¥)
Fiscal year ending December 31, 2025	176,000	105.1	150,000	157.7	185.20

Reference: Operating profit Fiscal year ending December 31, 2025 ¥192,000 million 53.2%

* Notes

(1) Changes in significant subsidiaries for the fiscal year ended December 31, 2024 Yes

Newly included: 2 companies Orchard Therapeutics Limited Excluded: —
FANCL Corporation

(2) Changes in accounting policies and changes in accounting estimates

i. Changes in accounting policies required by IFRS: None
ii. Changes in accounting policies due to other reasons: None
iii. Changes in accounting estimates: None

(3) Number of shares outstanding (ordinary shares)

i. Number of shares outstanding at the end of the period (including treasury shares)

As of December 31, 2024 914,000,000 shares
As of December 31, 2023 914,000,000 shares

ii. Number of treasury shares at the end of the period

As of December 31, 2024 104,005,638 shares
As of December 31, 2023 104,126,200 shares

iii. Average number of shares during the period

For the fiscal year ended December 31, 2024 809,943,818 shares
For the fiscal year ended December 31, 2023 809,853,429 shares

Note: Number of treasury shares at the end of the period includes shares held in the BIP (Board Incentive Plan) Trust (1,761,412 shares at December 31, 2024 and 1,911,065 shares at December 31, 2023). These shares are excluded in calculation of the average number of shares during the period.

* The summary of consolidated financial results is not subject to audit by certified public accountants or an audit corporation.
* Information about proper usage of forecast business results, and other special instructions

(1) The statements concerning future performance that are presented in this document are based on judgments using information available to Kirin Holdings and the Kirin Group as of the release date of this material. Certain risks and uncertainties could cause the results of Kirin Holdings and the Kirin Group to differ materially from any projections presented herein. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company's businesses, market trends, and exchange rates.

(2) The Company will post the Supplementary Documents to the Financial Results today, Friday, February 14, and will post the presentation materials from the financial results presentation to be held on Monday, February 17, the presentation content (video) and the main Q&A at the meeting as soon as possible on the Company's website.
(URL of the Company's website)
https://www.kirinholdings.com/en/investors/

ATTACHED MATERIALS

INDEX

1. KIRIN GROUP'S CURRENT BUSINESS PERFORMANCE 2

(1) STATEMENT OF BUSINESS ACTIVITIES AND RESULTS 2

(2) FINANCIAL POSITION 9

(3) BASIC POLICY AND DISTRIBUTION OF PROFITS AND DIVIDEND FOR 2024 AND 2025 10

2. BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS 11

3. CONSOLIDATED FINANCIAL STATEMENTS 12

(1) CONSOLIDATED STATEMENT OF FINANCIAL POSITION 12

(2) CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND COMPREHENSIVE INCOME 14

CONSOLIDATED STATEMENT OF PROFIT OR LOSS 14

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 15

(3) CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 16

(4) CONSOLIDATED STATEMENT OF CASH FLOWS 18

(5) NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 20

(GOING CONCERN ASSUMPTION) 20

(SEGMENT INFORMATION) 20

(CASH FLOW STATEMENT) 25

(PER SHARE INFORMATION) 26

(SIGNIFICANT SUBSEQUENT EVENTS) 27

4. OTHER 28

CHANGES OF DIRECTORS AND BOARD MEMBERS 28

1. KIRIN GROUP'S CURRENT BUSINESS PERFORMANCE

(1) STATEMENT OF BUSINESS ACTIVITIES AND RESULTS

In 2024, the environment surrounding the company has changed at an accelerating pace, with major economic and social consequences. Globally, conflicts and disputes among major powers have further heightened geopolitical tensions. Economically, the situation remains uncertain despite the calming of inflation, especially in the U.S., and the gradual recovery of the domestic economy.

In addition, environmental measures are urgently needed due to the frequency of extreme weather events and disasters in many countries around the world. In the digital ICT field, the practical application of generative AI and quantum technology is accelerating and having a significant impact on industry.

As the social environment undergoes major changes and becomes more complex, consumers' values and lifestyles are becoming more diverse than ever before, and we are entering an era of great change in which conventional wisdom is no longer applicable.

With "Creating Shared Value (CSV)" at the core of its management, the Kirin Group aims to achieve sustainable growth by flexibly responding to severe changes in the business environment through its unique business portfolio management, which includes health science in addition to alcoholic beverages, non-alcoholic beverages, and pharmaceuticals.

In 2024, in order to further evolve CSV management and increase the degree of strategy execution in each business, we shifted to a new management structure with two members, CEO and COO, and worked to maximize corporate value.

We created results in expansion of business profit in the alcoholic and non-alcoholic beverages business, strengthening of the global foundation of the pharmaceuticals business, and expansion of the scale of the health science business in line with the Kirin Group 2022-2024 Medium-Term Business Plan (2022-2024 MTBP) and achieved a record-high normalized operating profit, which is an indicator that measures the ongoing performance of a business. However, net profit attributable to owners of the Company decreased due to decisions made to lay the foundations for business growth, such as the loss on step acquisition associated with the consolidation of FANCL Corporation and the impact of the transfer of the amino acid business of Kyowa Hakko Bio Co.

In terms of ESG*1 initiatives, we have received high praise from external organizations, and for the fourth consecutive year, we have received an "AA" rating in the MSCI ESG Rating*2, an ESG index, on par with leading global companies in CSV management.

Kirin Holdings was also selected as one of the SX Brands*3 (Sustainability Transformation Brands) 2024 initiated by Japan's Ministry of Economy, Trade and Industry and the Tokyo Stock Exchange.

In addition, Kirin Holdings received the highest overall ranking for SDGs Management in the 6th Nikkei SDGs Management Survey for the sixth year in a row. Kirin Holdings' efforts to address social issues through its business operations and information disclosure of natural capital initiatives were highly praised.

*1 The initials from "Environmental," "Social," and "Governance," referring to corporate management and investment activities that consider these factors.

*2 A rating by Morgan Stanley Capital International (MSCI), Inc. of the United States, as measured by resilience to environmental, social, and governance risks, rated AAA-CCC.

*3 Launched by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange in 2024, this program selects companies

that promote sustainable corporate value creation.

Consolidated revenue	2,338.4 billion yen,	up	9.6%
Consolidated normalized operating profit*	211.0 billion yen,	up	4.7%
Consolidated profit before tax	139.7 billion yen,	down	29.1%
Consolidated profit attributable to owners of the Company	58.2 billion yen,	down	48.3%
(Key performance indicators)			
ROIC	4.1%		
Normalized EPS*	172 yen,	down	2.8%

* Operating profit:a profit indicator that measures the ordinary performance of the business by deducting the cost of sales and selling, general and administrative expenses from revenue

* Normalization: Non-recurring items such as Other operating income or expenses, etc. have been removed to more accurately reflect actual earnings.

Normalized EPS = Normalized profit / Average number of shares outstanding during period

Normalized profit = Profit attributable to Owners of the Company ± Other operating income and expenses and other items after income taxes

Results by segment are as follows.

Alcoholic Beverages Business

Kirin Brewery has achieved an attractive beer brand system by strengthening investment in its mainstay brands and introducing new products that meet consumer needs in anticipation of a single liquor tax in 2026.

We worked to revitalize the beer category by renewing **KIRIN ICHIBAN**, which has been on sale for 35 years, and **KIRIN ICHIBAN Zero Sugar**, which appeals to the health conscious, offering the delicious taste that only the KIRIN ICHIBAN production method can provide. Overall sales volume of the **KIRIN ICHIBAN** brand grew steadily, up 1% year on year.

We also launched a new standard beer brand, **Kirin Beer Harekaze**, for the first time in 17 years. We proposed a new taste of beer to our customers and nurtured it as a brand next to **KIRIN ICHIBAN**. As a result, it became a big hit, selling 1.3 times the annual target set at the time of its launch.

In craft beer, we renewed the **Spring Valley** brand and proposed ways to enjoy beer with diverse tastes. We also renewed and reopened Spring Valley Brewery Tokyo, a base for disseminating information about the brand, and worked to expand customer contacts in the craft beer market.

In the Japanese whisky category, domestic sales were up 20% year on year.

In particular, sales of **Kirin Whisky Riku** increased by 40% over the previous year due to an increase in the number of restaurants handling the product. **Kirin Whisky Fuji**, the flagship brand of FUJI-GOTEMBA DISTILLERY, received high acclaim, in addition to strong sales in Japan and expansion into new overseas markets, winning Gold in the Japanese whisky category at the International Spirits Challenge, a world-class liquor competition, for the second year in a row.

In RTDs, the mainstay **Kirin Hyoketsu®** brand performed well, growing 5% year on year. In particular, the **Kirin Hyoketsu® Sugar-Free** series grew significantly by 12% year on year, driving the overall growth of the brand. We also launched the **Kirin Hyoketsu® mottainai** series, which uses fruits that would otherwise be discarded due to standards issues, and gained the sympathy of customers as a new product that combines both good taste and social contribution.

Lion posted higher-than-market beer sales in Australia. In particular, **Stone & Wood** and **Hahn**, which meets health needs, performed well, and **XXXX** and several other brands also launched functional products to strengthen their sales base. In addition, **Hyoketsu**, which was launched in Australia and New Zealand, performed well thanks to the rollout of multiple flavors.

In North America, sales of **Voodoo Ranger**, a craft beer from New Belgium Brewing Company, were up from the previous year, while **Voodoo Hard Charged Tea**, an RTD product launched in 2024, performed well.

Alcoholic Beverages Business 2024 results:		
Consolidated revenue	1,081.7 billion yen, up	3.5%
Consolidated normalized operating profit	124.0 billion yen, up	3.4%

Non-alcoholic Beverages Business

Kirin Beverage focused on expanding health science beverages in addition to strengthening its core brands, and worked to improve profitability through cost reductions and price revisions.

In the **Gogo-no-Kocha** brand, we renewed the mainstay **Kirin Gogo-no-Kocha** and worked to increase demand for black tea throughout the year by proposing drinking scenarios such as iced tea in summer and hot milk tea in winter.

The **Kirin Nama-cha** brand was revitalized in the unsweetened tea market with the major renewal of **Kirin Nama-cha** and **Kirin Nama-cha Houjisencha**. The brand was well received not only for its taste, but also for its design, which was in line with customers' lifestyles and times, and its annual sales volume increased by 12% over the previous year.

In the health science beverages business, the **Kirin Oishii Immune Care** series, which was relaunched in March, achieved a significant year on year sales volume increase of 40% thanks to further promotion of an "immune care" habit. We also expanded our health science beverage lineup by strengthening functional beverages such as the **Healthya** brand of tea catechin drinks - which we acquired from Kao Corporation - and FANCL Corporation's **Calolimit®** brand.

Coke Northeast recorded strong sales, especially of carbonated beverages. Continuous optimization of operations, including the use of digital ICT, and pricing strategies tailored to market conditions drove profit growth for the entire group.

Non-alcoholic Beverages Business 2024 results:		
Consolidated revenue	564.9 billion yen, up	9.4%
Consolidated normalized operating profit	64.0 billion yen, up	22.2%

Pharmaceuticals Business

"Kyowa Kirin" drove growth with solid sales of **Crysvita***4 and **Poteligeo***5, products in the therapeutic areas of focus. In the development pipeline, clinical trials for **KHK4083/AMG451 (rocatinlimab)***6 progressed steadily, and we entered into a strategic alliance agreement with Kura Oncology, Inc. for the development and marketing of **ziftomenib***7. In addition, Kyowa Kirin promoted reforms aimed at sustainable growth as a Japanese Global Specialty Pharmaceutical Company from Japan, including the transformation of our global research structure to strengthen drug discovery capabilities, construction of a biopharmaceutical API manufacturing plant in North America, and restructuring of the Asia-Pacific business.

*4 A drug for the treatment of a rare disease that causes disorders of bone growth and metabolism, mainly due to genetic causes. It is marketed in Japan under the product name CRYSVITA.

*5 A drug for the treatment of certain blood cancers. It is marketed in Japan under the product name POTELIGEO.

*6 This product is under development for the treatment of atopic dermatitis. Clinical trials for prurigo nodosa and asthma are also ongoing.

*7 This product is developed for the treatment of acute leukemia.

Pharmaceuticals Business 2024 results:			
Consolidated revenue	495.3 billion yen,	up	12.1%
Consolidated normalized operating profit	91.9 billion yen,	down	4.3%

Health Science Business

With Blackmores Limited, based in Australia, as well as the acquisition of FANCL Corporation as a wholly owned subsidiary, we have established an operating base to become one of the largest health science companies in the Asia-Pacific region.

Blackmores Limited reported strong sales of its mainstay brand **Blackmores** and **BioCeuticals**, a dietary supplement for medical institutions, with sales revenue exceeding the previous year in all Asia-Pacific regions of operation.

Kyowa Hakko Bio Co., Ltd. is in the amino acid and human milk oligosaccharide (HMO) business, and it reached an agreement to transfer the amino acid and HMO business to Meihua Holdings Group, a leading bio-industry company in China. After the completion of the transfer, Kyowa Hakko Bio will focus on specialty materials, mainly citicoline, to improve profitability.

Health Science Business 2024 results:			
Consolidated revenue	175.3 billion yen,	up	69.6%
Consolidated normalized operating profit	(10.9) billion yen (12.5 billion yen loss in the previous year)		

<Outlook for 2025>

Coupled with the global political situation, the future economic outlook remains uncertain. In addition, climate change countermeasures due to global warming are urgently needed, and the environment surrounding management is piled with challenges.

In times of increasing uncertainty, the Kirin Group will make CSV a cornerstone of its management, solving social issues with the Group's strengths to create economic and social value.

We will develop a long-term vision for the next 10 years and transform our organizational structure to one that can quickly and flexibly optimize and execute strategies in response to any changes in the environment. We will actively invest in human resources, ICT, and R&D to improve our organizational capacity to achieve innovation.

In human resources, we will nurture employees who take on the challenge of creating value based on their expertise and diversity, while at the same time developing the systems and environment for this purpose.

In addition, we will expand the number of global human resources and career hires who will be responsible for future group management.

In ICT, we will promote value creation in marketing and R&D areas, etc., by utilizing digital technologies such as generative AI, and work to transform business processes throughout the Group. By promoting the division of labor between humans and AI, we will change the way we work and accelerate productivity improvement.

In R&D, we will use our technological capabilities based on fermentation and biotechnology, which are our strengths, to promote R&D linked to our business strategy, such as further adding value through functional research of LC-Plasma and the possibility of developing skincare products by utilizing FANCL Corporation's technology.

In addition, we have set as a common goal the strengthening of front-line capabilities to execute strategies in all businesses, and by working together with management and front-line personnel, we will strive to achieve group growth and strengthen our earnings base.

Through these efforts, we aim to achieve our financial targets for EPS and ROIC, as well as our non-financial targets for health, community, environment, and human capital.

Consolidated Earnings Forecasts for the Fiscal Year 2025:		
Consolidated revenue	2,440.0 billion yen, up	4.3%
Consolidated normalized operating profit	212.0 billion yen, up	0.5%
Consolidated profit before tax	230.0 billion yen, up	64.6%
Consolidated profit attributable to owners of the Company	150.0 billion yen, up	157.7%
(Key performance indicators)		
ROIC	7.2%	
Normalized EPS	185 yen	

1.Alcoholic Beverages Business

As customers' values toward alcoholic beverages are diversifying, Kirin Brewery will create the future of alcoholic beverages and create the pleasure of connecting with people and society, based on the premise of our CSV Purpose: being a “Responsible Alcohol Producer.” To grow our business, we aim to strengthen our earnings base by focusing on our main beer brands with an eye on the future market environment.

Under the **KIRIN ICHIBAN** brand, **Kirin Ichiban White Beer** will be released in April, offering new drinking opportunities to consumers.

Kirin Beer Harekaze will also begin to be sold in medium bottles for restaurants in April. We will continue to propose new tastes of beer and work to establish a firm foothold in the market through Harekaze ACTION, an initiative to preserve and pass on Japanese traditional customs and traditions. In craft beer, we will continue our efforts to make beer culture more attractive by substantially renewing the **Spring Valley** brand in March and actively collaborating with craft breweries around Japan.

Lion will strengthen sales of the **Hahn** beer brand in Australia, **Stone & Wood**, and **Hyoketsu**, which it markets in Australia and New Zealand. In North America, we will also work to expand sales of the RTD **Voodoo Hard Charged Tea** in addition to **Voodoo Ranger**, both from New Belgium Brewing Co.

2.Non-alcoholic Beverages Business

In the severely competitive environment of the domestic beverage market, Kirin Beverage is striving to grow its business with health science beverages as a driver, under the slogan “deliver tasty health to consumers every day.” In addition to the renewal of **Oishii Immune Care** and **iMUSE Yogurt** in March, we will propose drinking opportunities to a wide range of consumers. By promoting “immune care” as a daily health habit, we aim to further expand the market.

In the **Gogo-no-Kocha** brand, **Gogo-no-Kocha Oishii Muto** was renewed in March, and by promoting the appeal of unsweetened black tea, we aim to expand the black tea market and strengthen the unsweetened tea market as well.

Coke Northeast will focus on strong soda products, and will work on a pricing strategy tailored to the market environment, while improving supply chain efficiency, including digital ICT, to ensure high profitability.

3.Pharmaceuticals Business

As a Global Specialty Pharmaceutical Company from Japan, Kyowa Kirin will accelerate its efforts to create "life-changing" value that will bring smiles to the faces of people facing illness.

To further solidify our management structure, we have changed to a two-person CEO and COO structure, aiming for a further leap forward.

In addition to aiming to increase profits through the growth of **Crysvita** and **Poteligeo**, which are products in Kyowa Kirin's therapeutic areas of focus, Kyowa Kirin will steadily promote the development and launch of **KHK4083** and **ziftomenib** in order to enhance its pipeline. We will also work to strengthen our global R&D capabilities.

4.Health Science Business

As the market grows significantly due to increasing health consciousness, the Kirin Group aims to grow faster than the market in order to realize the joy of living and happy and healthy lifestyles for people in all regions where we do business. FANCL Corporation, Blackmores Limited, and Kirin Holdings will maximize the value they provide through their respective growth and the swift achievement of the benefits of integration.

FANCL Corporation will achieve further growth in the Cosmetics business and health food businesses in Japan.

FANCL Corporation and Kirin Holdings will work to create value by leveraging the strengths of both companies, for example by combining FANCL Corporation's customer analysis capabilities through direct channels with Kirin Holdings' market research capabilities to develop new products.

Overseas, in addition to nurturing the brand in China, FANCL Corporation will expand into Southeast Asia and other regions through collaboration with Blackmores Limited.

Blackmores Limited aims to achieve sustained growth of the **Blackmores** and **BioCeuticals** brands in Australia and New Zealand, and to increase revenues in China and Southeast Asia.

In the LC-Plasma business, Kirin Holdings aims to improve profitability through expansion of value-added products and overseas expansion in collaboration with Blackmores, aiming for further growth. In the domestic supplement business, Kirin Holdings aims to improve operating efficiency and profitability by integrating its sales base with that of FANCL Corporation.

We will also accelerate the creation of new synergies between health science and pharmaceuticals. Kirin Holdings Company and Kyowa Kirin Company established Cowellnex Corporation in September 2024 as a joint venture. Cowellnex exists in the Kirin Group's Innovation Center, and through innovation that combines the strengths of both companies in health-related research and business development, we will work to solve social issues surrounding health.

The Kirin Group will continue to strive to be the company you have come to expect as a company that achieves sustainable growth through high strategic execution and unique business portfolio management, and with our sights set on KV2027, we aim to raise the stage for becoming one of the world's leading CSV companies by ensuring that each and every employee continues to challenge themselves to achieve innovation.

(2) FINANCIAL POSITION

Total assets at the end of the current consolidated fiscal year were 3,354.2 billion yen, an increase of 484.6 billion yen from the end of the previous consolidated fiscal year mainly due to an increase in property, plant and equipment, goodwill and intangible assets due to the FANCL step acquisition.

Equity increased by 107.9 billion yen from the end of the previous consolidated fiscal year to 1,533.7 billion yen mainly due to an increase in non-controlling interests as a result of the FANCL step acquisition and an increase in reserves due to foreign exchange fluctuations.

Liabilities increased by 376.7 billion yen from the end of the previous consolidated fiscal year to 1,820.4 billion yen mainly due to an increase in deferred tax liabilities, new bonds and borrowings in relation to the FANCL step acquisition.

The balance of cash and cash equivalents (hereinafter referred to as "net cash") at the end of the current consolidated fiscal year was 118.6 billion yen, a decrease of 12.8 billion yen from the end of the previous consolidated fiscal year. Consolidated cash flows were as follows:

Cash flows from operating activities

Net cash provided by operating activities increased by 39.6 billion yen year on year to 242.8 billion yen. This was due to the recording of 139.7 billion yen in profit before tax and 95.7 billion yen in adjustment for depreciation and amortization, while outflow of working capital decreased by 2.4 billion yen year on year, and income taxes paid increased by 14.2 billion yen year on year.

Cash flows from investing activities

Net cash used in investing activities increased by 103.3 billion yen year on year to 329.4 billion yen. There was an inflow of 7.4 billion yen for sale of investees and 5.7 billion yen for sale of property, plant and equipment and intangible assets, while there was an outflow of 180.6 billion yen for acquisition of property, plant and equipment and intangible assets, representing an increase by 66.8 billion yen year on year, and 159.8 billion yen for acquisition of subsidiaries.

Cash flows from financing activities

Net cash provided by financing activities increased by 22.2 billion yen year on year to 58.1 billion yen. There was an outflow of 78.4 billion yen for repayment of long-term borrowings, 72.7 billion yen for dividends paid, 40.0 billion yen for acquisition of treasury shares by a consolidated subsidiary, 30.0 billion yen for payment for redemption of bonds and 20.2 billion yen for repayment of lease liabilities, while there were proceeds of 296.9 billion yen from long-term borrowings and 13.0 billion yen for increase in commercial paper.

(3) BASIC POLICY AND DISTRIBUTION OF PROFITS AND DIVIDEND FOR 2024 AND 2025

Kirin will allocate resources to its businesses and distribute profits to its shareholders as set out below.

Regarding resource allocation to businesses, giving top priority to investments that contribute to further developing businesses with a focus on the Heath Science domain, Kirin will make investments that contribute to enhancement of existing businesses and profit improvement. Kirin will also implement a stable and continuous allocation of resources to intangible assets (such as brands, research and development, information and communication technology (ICT), and human resources) that sustain the growth of future cash flows. Kirin will take a disciplined approach to investments in terms of maintaining and improving the Kirin Group's capital efficiency.

Kirin also views the appropriate distribution of profits to shareholders as a key management objective. With regard to the distribution of surplus funds for 2024, based on a consolidated dividend payout ratio on normalized EPS of at least 40%, Kirin's Board of Directors made a resolution for an interim dividend of 35.5 yen per share and a year-end dividend of 35.5 yen per share, for an annual dividend totaling 71 yen per share (the same amount per share as the previous year). The year-end dividend will be determined at the 186th General Meeting of Shareholders scheduled for March 28, 2025.

Kirin will continue to consider opportunities to acquire treasury shares as additional shareholder returns, comprehensively taking into account various factors including optimum capital structure, market conditions and reserve funds after investments.

From the next fiscal year onwards, in order to achieve more stable and sustainable dividends, we will change our dividend policy to one that, in principle, implements progressive dividends, with a target DOE (dividend on equity) of 5% or more. As part of management that is conscious of capital costs with the aim of increasing corporate value, we will strive to further enhance the return of profits to shareholders and improve capital efficiency.

Regarding the distribution of surplus funds for 2025, Kirin plans to pay a full-year dividend of 74 yen per share.

2. BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS

The Kirin Group has adopted International Financial Reporting Standards ("IFRS") from the fiscal year ended December 31, 2017 to enhance the international comparability of its financial information in the capital markets.

3. CONSOLIDATED FINANCIAL STATEMENTS

(1) CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(¥ millions)

	At December 31, 2023	At December 31, 2024
Assets		
Non-current assets		
Property, plant and equipment	592,928	674,028
Goodwill	390,568	501,480
Intangible assets	303,540	659,561
Equity-accounted investees	370,720	216,205
Other financial assets	105,346	103,360
Other non-current assets	39,340	48,570
Deferred tax assets	109,322	109,761
Total non-current assets	1,911,764	2,312,966
Current assets		
Inventories	330,984	358,985
Trade and other receivables	444,940	502,880
Other financial assets	8,944	8,570
Other current assets	41,556	52,142
Cash and cash equivalents	131,399	118,617
Total current assets	957,821	1,041,193
Total assets	2,869,585	3,354,159

(¥ millions)

	At December 31, 2023	At December 31, 2024
Equity		
Share capital	102,046	102,046
Share premium	21,150	9,497
Retained earnings	1,128,541	1,130,931
Treasury shares	(251,675)	(251,376)
Reserves	132,519	190,427
Equity attributable to owners of the Company	1,132,581	1,181,525
Non-controlling interests	293,257	352,189
Total equity	1,425,838	1,533,714
Liabilities		
Non-current liabilities		-
Bonds and borrowings	555,725	779,583
Other financial liabilities	82,914	87,398
Defined benefit liability	55,228	54,986
Provisions	4,316	7,100
Liabilities from application of equity method	13,966	10,458
Other non-current liabilities	19,921	13,622
Deferred tax liabilities	38,871	123,233
Total non-current liabilities	770,941	1,076,380
Current liabilities		
Bonds and borrowings	100,673	77,986
Trade and other payables	306,670	364,265
Other financial liabilities	61,720	54,935
Current tax liabilities	9,687	11,428
Provisions	4,153	12,214
Other current liabilities	189,904	223,238
Total current liabilities	672,806	744,065
Total liabilities	1,443,747	1,820,445
Total equity and liabilities	2,869,585	3,354,159

(2) CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND COMPREHENSIVE INCOME

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

(¥ millions)

	Year ended December 31, 2023	Year ended December 31, 2024
Revenue	2,134,393	2,338,385
Cost of sales	1,170,927	1,272,430
Gross profit	963,466	1,065,955
Selling, general and administrative expenses	761,971	854,987
Normalized operating profit	201,495	210,968
Other operating income	28,835	16,145
Other operating expenses	80,036	101,773
Operating profit	150,294	125,340
Finance income	9,035	14,595
Finance costs	10,523	17,994
Share of profit of equity-accounted investees	32,773	37,035
Gain on sale of equity-accounted investees	15,470	—
Impairment loss on equity-accounted investees	—	19,255
Profit before tax	197,049	139,721
Income tax expense	46,611	53,910
Profit	150,438	85,811
Profit attributable to:		
Owners of the Company	112,697	58,214
Non-controlling interests	37,741	27,597
Profit	150,438	85,811
Earnings per share (¥)		
Basic earnings per share	139.16	71.87
Diluted earnings per share	139.15	71.86

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(¥ millions)

	Year ended December 31, 2023	Year ended December 31, 2024
Profit	150,438	85,811
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Net change in equity instruments measured at fair value through other comprehensive income	7,854	476
Remeasurements of defined benefit plans	6,273	4,213
Share of other comprehensive income of equity-accounted investees	(1,504)	(690)
Items that are or may be reclassified to profit or loss		
Foreign currency translation differences on foreign operations	93,125	68,758
Cash flow hedges	(1,100)	3,521
Share of other comprehensive income of equity-accounted investees	6,715	(3,902)
Total other comprehensive income	111,362	72,376
Comprehensive income	261,801	158,187
Comprehensive income attributable to:		
Owners of the Company	214,321	118,626
Non-controlling interests	47,480	39,561
Comprehensive income	261,801	158,187

(3) CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Year ended December 31, 2023

(¥ millions)

	Equity attributable to owners of the Company					
					Reserves	
	Share capital	Share premium	Retained earnings	Treasury shares	Net change in equity instruments measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance at January 1, 2023	102,046	25,519	1,063,823	(251,788)	16,826	—
Profit	—	—	112,697	—	—	—
Other comprehensive income	—	—	—	—	7,318	4,503
Comprehensive income	—	—	112,697	—	7,318	4,503
Dividends from surplus	—	—	(57,500)	—	—	—
Acquisition of treasury shares	—	—	—	(21)	—	—
Disposal of treasury shares	—	(0)	—	2	—	—
Change in scope of consolidation	—	—	—	—	—	—
Share-based payments	—	220	(7)	132	—	—
Changes in the ownership interest in a subsidiary without a loss of control	—	(4,589)	—	—	—	—
Transfer from reserves to retained earnings	—	—	9,528	—	(5,025)	(4,503)
Total transactions with owners of the Company	—	(4,369)	(47,978)	113	(5,025)	(4,503)
Balance at December 31, 2023	102,046	21,150	1,128,541	(251,675)	19,119	—

	Equity attributable to owners of the Company				Non-controlling interests	Total equity
	Reserves			Total		
	Foreign currency translation differences on foreign operations	Cash flow hedges	Total			
Balance at January 1, 2023	24,585	(988)	40,423	980,022	273,181	1,253,203
Profit	—	—	—	112,697	37,741	150,438
Other comprehensive income	90,077	(275)	101,624	101,624	9,739	111,362
Comprehensive income	90,077	(275)	101,624	214,321	47,480	261,801
Dividends from surplus	—	—	—	(57,500)	(13,742)	(71,242)
Acquisition of treasury shares	—	—	—	(21)	—	(21)
Disposal of treasury shares	—	—	—	1	—	1
Change in scope of consolidation	—	—	—	—	(18,726)	(18,726)
Share-based payments	—	—	—	346	(117)	229
Changes in the ownership interest in a subsidiary without a loss of control	—	—	—	(4,589)	5,181	592
Transfer from reserves to retained earnings	—	—	(9,528)	—	—	—
Total transactions with owners of the Company	—	—	(9,528)	(61,762)	(27,403)	(89,166)
Balance at December 31, 2023	114,662	(1,263)	132,519	1,132,581	293,257	1,425,838

Year ended December 31, 2024

(¥ millions)

	Equity attributable to owners of the Company					
					Reserves	
	Share capital	Share premium	Retained earnings	Treasury shares	Net change in equity instruments measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance at January 1, 2024	102,046	21,150	1,128,541	(251,675)	19,119	—
Profit	—	—	58,214	—	—	—
Other comprehensive income	—	—	—	—	753	2,308
Comprehensive income	—	—	58,214	—	753	2,308
Dividends from surplus	—	—	(58,316)	—	—	—
Acquisition of treasury shares	—	—	—	(65)	—	—
Disposal of treasury shares	—	(0)	—	2	—	—
Change in scope of consolidation	—	—	—	—	—	—
Share-based payments	—	(85)	(11)	361	—	—
Changes in the ownership interest in a subsidiary without a loss of control	—	(11,567)	—	—	—	—
Transfer from reserves to retained earnings	—	—	2,503	—	(196)	(2,308)
Total transactions with owners of the Company	—	(11,652)	(55,824)	298	(196)	(2,308)
Balance at December 31, 2024	102,046	9,497	1,130,931	(251,376)	19,676	—

	Equity attributable to owners of the Company				Non-controlling interests	Total equity
	Reserves			Total		
	Foreign currency translation differences on foreign operations	Cash flow hedges	Total			
Balance at January 1, 2024	114,662	(1,263)	132,519	1,132,581	293,257	1,425,838
Profit	—	—	—	58,214	27,597	85,811
Other comprehensive income	54,649	2,702	60,412	60,412	11,964	72,376
Comprehensive income	54,649	2,702	60,412	118,626	39,561	158,187
Dividends from surplus	—	—	—	(58,316)	(14,383)	(72,699)
Acquisition of treasury shares	—	—	—	(65)	—	(65)
Disposal of treasury shares	—	—	—	2	—	2
Change in scope of consolidation	—	—	—	—	62,438	62,438
Share-based payments	—	—	—	265	(75)	190
Changes in the ownership interest in a subsidiary without a loss of control	—	—	—	(11,567)	(28,609)	(40,176)
Transfer from reserves to retained earnings	—	—	(2,503)	—	—	—
Total transactions with owners of the Company	—	—	(2,503)	(69,682)	19,371	(50,310)
Balance at December 31, 2024	169,311	1,440	190,427	1,181,525	352,189	1,533,714

(4) CONSOLIDATED STATEMENT OF CASH FLOWS

(¥ millions)

	Year ended December 31, 2023	Year ended December 31, 2024
Cash flows from operating activities		
Profit before tax	197,049	139,721
Depreciation and amortization	87,227	95,702
Impairment losses	29,987	13,389
Interest and dividends received	(4,120)	(11,103)
Share of profit of equity-accounted investees	(32,773)	(37,035)
Interest paid	5,932	6,916
Loss on step acquisitions	—	18,265
Gain on sale of property, plant and equipment and intangible assets	(6,119)	(3,713)
Loss on disposal and sale of property, plant and equipment and intangible assets	2,616	4,925
Gain on sale of shares of subsidiaries	(14,822)	(7,372)
Loss on sale of shares of subsidiaries	19,358	—
Gain on sale of equity-accounted investees	(15,470)	—
Impairment loss on equity-accounted investees	—	19,255
(Increase) decrease in trade receivables	(13,365)	(34,894)
(Increase) decrease in inventories	(20,063)	(4,888)
Increase (decrease) in trade payables	10,972	18,240
Increase (decrease) in liquor taxes payable	434	1,942
Other	(29,403)	43,977
Sub-total	217,440	263,325
Interest and dividends received	27,855	36,852
Interest paid	(5,441)	(6,522)
Income taxes paid	(36,647)	(50,811)
Cash flows from (used in) operating activities	203,206	242,844

(¥ millions)

	Year ended December 31, 2023	Year ended December 31, 2024
Cash flows from investing activities		
Acquisition of property, plant and equipment and intangible assets	(113,810)	(180,584)
Proceeds from sale of property, plant and equipment and intangible assets	7,465	5,662
Acquisition of investments	(1,380)	(3,964)
Proceeds from sale of investments	7,990	7,358
Acquisition of shares of subsidiaries, net of cash acquired	(162,097)	(159,830)
Payment for sale of shares of subsidiaries, net of cash disposed of	(5,006)	—
Proceeds from sale of shares of subsidiaries, net of cash disposed of	8,024	1,343
Acquisition of equity-accounted investees	(18)	(5)
Proceeds from sale of equity-accounted investees	24,017	3,513
Other	8,723	(2,869)
Cash flows from (used in) investing activities	(226,091)	(329,375)
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	(1,900)	(717)
Increase (decrease) in commercial paper	(18,000)	12,999
Proceeds from long-term borrowings	171,532	296,904
Repayment of long-term borrowings	(63,478)	(78,413)
Proceeds from issuance of bonds	93,000	—
Payment for redemption of bonds	(55,000)	(30,000)
Payment for redemption of bonds with subscription rights to shares	—	(9,621)
Repayment of lease liabilities	(18,621)	(20,223)
Payment for acquisition of treasury shares	(25)	(82)
Payment for acquisition of treasury shares by a consolidated subsidiary	(10)	(40,018)
Dividends paid	(57,500)	(58,316)
Dividends paid to non-controlling interests	(13,660)	(14,381)
Other	(428)	(8)
Cash flows from (used in) financing activities	35,909	58,125
Effect of exchange rate changes on cash and cash equivalents	4,832	15,624
Net increase (decrease) in cash and cash equivalents	17,855	(12,782)
Cash and cash equivalents at beginning of year	88,060	131,399
Net increase (decrease) in cash and cash equivalents resulting from transfers to assets held for sale	25,484	—
Cash and cash equivalents at end of year	131,399	118,617

(5) NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(GOING CONCERN ASSUMPTION)

There are no matters to report under this item.

(SEGMENT INFORMATION)

(1) Summary of reportable segments

The reportable segments of the Group are determined based on the operating segments which are constituent units of the Group for which separate financial information is readily available, and which are periodically examined by the Board of Directors for the purpose of deciding the allocation of management resources and evaluating the business results. The Group has identified four reportable segments, namely, "Alcoholic Beverages Business," "Non-alcoholic Beverages Business," "Pharmaceuticals Business" and "Health Science Business."

"Alcoholic Beverages Business," for which Kirin Brewery Company, Limited, Lion Pty Limited and other entities operate businesses in Japan and overseas. Kirin Brewery Company, Limited conducts production and sale of alcoholic beverages such as beer, low alcohol drinks and other products in Japan while Lion Pty Limited conducts production and sale of beer, low alcohol drinks and other products in the Oceania region and other regions, and production and sale of craft beer and other products in North America.

"Non-alcoholic Beverages Business," for which Kirin Beverage Company, Limited and Coca-Cola Beverages Northeast, Inc. and other entities operate businesses in Japan and overseas. Kirin Beverage Company, Limited conducts production and sale of soft drinks in Japan while Coca-Cola Beverages Northeast, Inc. conducts production and sale of Coca-Cola in the U.S.

"Pharmaceuticals Business," for which Kyowa Kirin Co., Ltd. and other entities conduct production and sale of pharmaceutical products in Japan and overseas.

"Health Science Business," for which FANCL Corporation, Blackmores Limited, Kyowa Hakko Bio Co., Ltd. and other entities operate natural health and other businesses in Japan and overseas. FANCL Corporation conducts research and development, production and sale of health food and cosmetics. Blackmores Limited conducts production and sale of nutritional supplements and related products in Australia, Southeast Asia and other regions, while Kyowa Hakko Bio Co., Ltd. conducts production and sale of active pharmaceutical ingredient, amino acid and natural health products. The Company acquired FANCL Corporation in the current year, which as noted above is categorized and reported in the "Health Science Business.

Accounting policies for segment information are generally the same as those in the Company's consolidated financial statements.

Inter-segment revenue is based on actual market prices.

(2) Change in reportable segments

The Group identified its reportable segments as "Japan Beer and Spirits Businesses," "Japan Non-alcoholic Beverages Business," "Oceania Adult Beverages Business" and "Pharmaceuticals Business" until the year ended December 31, 2023, and has reorganized its reportable segments into "Alcoholic Beverages Business," "Non-alcoholic Beverages Business," "Pharmaceuticals Business," and "Health Science Business" from the year ended December 31, 2024.

"KV2027" sets the Long-Term Management Vision for the Group to become a global leader in CSV, creating value across our world of Food & Beverages and Pharmaceuticals domains. To achieve the Long-Term Management Vision, the Company is working on making the Health Science domain a third pillar of the Company's business and acquired 100% of the shares of Blackmores Limited, an Australian-based company, to make it a subsidiary during the year ended December 31, 2023. With this acquisition, the Group will expand its business scale in the Health Science domain. Accordingly, the Board meeting held on November 20, 2023 resolved a change in the internal monitoring units of the Group from the year

ending December 31, 2024.
Therefore, the Group determined "Alcoholic Beverages Business," "Non-alcoholic Beverages Business," (Food & Beverages domain) "Pharmaceuticals Business," (Pharmaceuticals domain) and "Health Science Business." (Health Science domain) to be disclosed separately as reportable segments from the year ending December 31, 2024.
Segment information for the previous fiscal year has been prepared based on the revised reportable segments.

(3) Information on reportable segments

Information related to each reportable segment is set out below.

At and for the fiscal year ended December 31, 2023

(¥ millions)

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science			
Revenue from unaffiliated customers	1,045,138	516,171	441,882	103,354	27,847	—	2,134,393
Inter-segment revenue	2,336	2,771	351	4,694	66,241	(76,393)	—
Total revenue	1,047,473	518,942	442,233	108,048	94,089	(76,393)	2,134,393
Segment income (loss) (Note 3)	119,939	52,358	95,968	(12,535)	(60)	(54,175)	201,495

Other operating income	28,835
Other operating expenses	80,036
Finance income	9,035
Finance costs	10,523
Share of profit of equity-accounted investees	32,773
Gain on sale of equity-accounted investees	15,470
Profit before tax	197,049

(¥ millions)

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science			
Segment assets	1,331,859	287,563	971,375	472,230	532,349	(725,791)	2,869,585
Other items							
Depreciation and amortization	35,296	12,719	20,938	5,172	3,803	9,299	87,227
Impairment losses (excluding financial assets)	2,476	—	10,843	16,668	—	—	29,987
Equity-accounted investees	229,501	—	12,357	128,863	—	—	370,720
Capital expenditures	39,098	24,242	33,273	10,127	2,723	10,283	119,745

Notes: 1. "Others" includes segments which are not included in the reportable segments

2. Adjustments are as follows:

(1) Adjustment in segment income mainly includes inter-segment eliminations and corporate expenses not attributable to any reportable segment. The expenses are mainly group administrative expenses incurred by the Company, a holding company, and administrative expenses relating to some reportable segments incurred by shared services companies.

(2) Adjustment in segment assets includes inter-segment asset and liability eliminations and corporate assets not attributable to any reportable segment. The assets mainly consist of surplus funds (cash), long-term investments (equity instruments) and assets of the administrative department of the Company, a holding company, and shared services companies.

3. Segment income (loss) represents normalized operating profit which is calculated by deducting the total of cost of sales and selling, general and administrative expenses from revenue.

At and for the fiscal year ended December 31, 2024

(¥ millions)

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science			
Revenue from unaffiliated customers	1,081,694	564,871	495,295	175,256	21,270	—	2,338,385
Inter-segment revenue	2,319	2,967	264	4,217	76,659	(86,425)	—
Total revenue	1,084,013	567,837	495,558	179,473	97,929	(86,425)	2,338,385
Segment income (loss) (Note 3)	124,045	63,961	91,866	(10,895)	30	(58,040)	210,968
Other operating income							16,145
Other operating expenses							101,773
Finance income							14,595
Finance costs							17,994
Share of profit of equity-accounted investees							37,035
Impairment loss on equity-accounted investees							19,255
Profit before tax							139,721

(¥ millions)

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science			
Segment assets	1,368,009	326,366	1,016,051	636,950	392,559	(385,776)	3,354,159
Other items							
Depreciation and amortization	36,070	12,778	24,780	8,937	3,753	9,383	95,702
Impairment losses (excluding financial assets)	3,902	—	2,060	7,427	—	—	13,389
Equity-accounted investees	213,065	—	3,139	—	—	—	216,205
Capital expenditures	39,024	20,897	109,474	6,683	7,172	10,358	193,607

Notes: 1. "Others" includes segments which are not included in the reportable segments.

2. Adjustments are as follows:

(1) Adjustment in segment income mainly includes inter-segment eliminations and corporate expenses not attributable to any reportable segment. The expenses are mainly group administrative expenses incurred by the Company, a holding company, and administrative expenses relating to some reportable segments incurred by shared services companies.

(2) Adjustment in segment assets includes inter-segment asset and liability eliminations and corporate assets not attributable to any reportable segment. The assets mainly consist of surplus funds (cash), long-term investments (equity instruments) and assets of the administrative department of the Company, a holding company, and shared services companies.

3. Segment income (loss) represents normalized operating profit which is calculated by deducting the total of cost of sales and selling, general and administrative expenses from revenue.

(4) Geographic information

1) Revenue

(¥ millions)

	Year ended December 31, 2023	Year ended December 31, 2024
Japan	1,183,300	1,214,171
Oceania	213,876	234,529
America	539,076	631,040
Others	198,140	258,644
Total	2,134,393	2,338,385

Note: Revenue is classified by country or area based on customer location.

2) Non-current assets

(¥ millions)

	At December 31, 2023	At December 31, 2024
Japan	482,720	906,390
Oceania	463,968	455,852
America	229,863	296,476
Others	118,904	188,524
Total	1,295,455	1,847,242

Note: Non-current assets exclude financial instruments, deferred tax assets and defined benefit assets.

(5) Major customer

The unaffiliated customer which accounted for 10% or more of revenue on the consolidated statement of profit or loss was as follows:

(¥ millions)

	Related segment	Year ended December 31, 2023	Year ended December 31, 2024
Mitsubishi Shokuhin Co., Ltd.	Alcoholic Beverages, Non-alcoholic Beverages, Health Science	230,872	234,844

(CASH FLOW STATEMENT)

FANCL step acquisition

(1) Outline of the transaction

On September 19, 2024, the Company acquired an additional 42.72% of voting rights in FANCL Corporation through a tender offer. As a result, combined with its previously held interests, the Company now holds 75.24 % of voting rights in FANCL Corporation, and obtained control.

1) Name and business of the acquiree

Name of the acquiree	FANCL Corporation
Business outline	R&D, manufacturing and sale of cosmetics and health food

2) Acquisition date

September 19, 2024

3) How the acquirer obtained control of the acquiree

Acquisition of shares for cash consideration

4) Percentage of voting rights acquired

Percentage of voting rights before acquisition: 32.52%

Percentage of voting rights after acquisition: 75.24% (after accounting for diluted shares)

(2) Breakdown of consideration

Fair value of the acquiree's shares previously held as of the acquisition date	¥ 110,713 million
Cash consideration for additional shares acquired	¥ 145,451 million
Total consideration	¥ 256,164 million

(3) Relationship between consideration for acquisition and expenditures for acquisition of shares of subsidiaries

(¥ millions)

Item	Amount
Consideration for acquisition	256,164
Fair value of the acquiree's shares previously held as of the acquisition date	110,713
Cash and cash equivalents held by the acquiree	33,816
Acquisition of shares of subsidiaries, net of cash acquired	111,635

As a result of remeasurement of the Company's previously held interests in FANCL Corporation to the fair value as of the acquisition date, ¥18,265 million of loss on step acquisition was recognized in other operating expenses in the consolidated statement of profit or loss.

Regarding the fractional shares resulting from the reverse stock split that took effect on December 20, 2024, the sale to the Company has not been completed as of December 31, 2024. Therefore, the Company's ownership interest in FANCL Corporation is accounted for as 75.62%.

(PER SHARE INFORMATION)

(1) Basis of calculation of basic earnings per share

The basis of calculation of basic earnings per share is as follows:

1) Profit attributable to ordinary shareholders of the Company (basic)

(¥ millions)

	Year ended December 31, 2023	Year ended December 31, 2024
Profit attributable to owners of the Company	112,697	58,214
Profit not attributable to ordinary shareholders of the Company	—	—
Profit attributable to ordinary shareholders of the Company	112,697	58,214

2) Weighted-average number of ordinary shares (basic)

(Thousands of shares)

	Year ended December 31, 2023	Year ended December 31, 2024
Weighted-average number of ordinary shares	809,853	809,944

(2) Basis of calculation of diluted earnings per share

Diluted earnings per share is calculated as follows based on profit attributable to ordinary shareholders of the Company and weighted-average number of ordinary shares outstanding after adjustment for the effects of all potentially dilutive ordinary shares:

1) Profit attributable to ordinary shareholders of the Company (diluted)

(¥ millions)

	Year ended December 31, 2023	Year ended December 31, 2024
Profit attributable to ordinary shareholders of the Company	112,697	58,214
Adjustments for potential ordinary shares issued by a subsidiary	(6)	(9)
Profit attributable to ordinary shareholders of the Company (diluted)	112,691	58,205

2) Weighted-average number of ordinary shares (diluted)

(Thousands of shares)

	Year ended December 31, 2023	Year ended December 31, 2024
Weighted-average number of ordinary shares (basic)	809,853	809,944
Effect of dilution	—	—
Weighted-average number of ordinary shares (diluted)	809,853	809,944

(SIGNIFICANT SUBSEQUENT EVENTS)

There are no matters to report under this item.

4. OTHER

Changes of Directors and Board Members

Kirin Holdings Company, Limited hereby announces the changes of Directors and Board Members as follows (Scheduled at the end of March 2025).

1. Changes of Representatives

(1) New Representative Director

None

(2) Retiring Representative Director

None

Note: Yoshinori Isozaki (Representative Director of the Board & CEO), Takeshi Minakata (Representative Director of the Board, President & COO) are scheduled to be reappointed.

2. Changes of Other Directors of the Board

(1) New Directors of the Board

Name	New appointment	Current tittle
Shingo Konomoto	Kirin Holdings Company, Limited Independent Non-executive Director of the Board	Nomura Research Institute, Ltd. Chairman, Member of the Board
Naoko Mikami	Kirin Holdings Company, Limited Independent Non-executive Director of the Board	

(2) Retiring Directors of the Board

Name	New appointment	Current tittle
Masakatsu Mori	Retirement	Kirin Holdings Company, Limited Independent Non-executive Director of the Board
George Olcott	Retirement	Kirin Holdings Company, Limited Independent Non-executive Director of the Board

Note: (i)Junko Tsuboi; (ii)Toru Yoshimura and Shinjiro Akieda; and (iii) Hiroyuki Yanagi, Noriko Shiono, Rod Eddington, Shinya Katanozaka and Yoshiko Ando are scheduled to be reappointed as (i) Director of the Board, Senior Executive Vice President, (ii) Directors of the Board, Senior Executive Officers, and (iii) Non-executive Directors of the Board, respectively.

3. Changes of Audit & Supervisory Board Members

(1) New Audit & Supervisory Board Members

None

(2) Retiring Audit & Supervisory Board Members

None

Note: Shobu Nishitani and Toru Ishikura as Standing Audit & Supervisory Board Members, and Kaoru Kashima, Kenichi Fujinawa and Yoko Dochi as Audit & Supervisory Board Members are during their term of office.

Profile of candidates for the new Director of the Board

Shingo Konomoto

Date of birth:	February 11, 1960
Experience:	
June 2024-present	Non-executive Director of the Board, Sony Group Corporation
June 2024-present	Chairman, Member of the Board of Nomura Research Institute, Ltd.
April 2024	Chairman, Member of the Board, Representative Director of Nomura Research Institute, Ltd.
June 2019	Chairman and President & CEO, Member of the Board, Representative Director of Nomura Research Institute, Ltd.
April 2016	President & CEO, Member of the Board, Representative Director, of Nomura Research Institute, Ltd.
June 2015	Senior Executive Managing Director, Member of the Board, Representative Director, Supervising of Business Divisions, Head of Consulting of Nomura Research Institute, Ltd.
April 2010	Senior Corporate Managing Director, Division Manager of Consulting Division of Nomura Research Institute, Ltd.
April 2004	Senior Managing Director, Division Manager of Consulting Division Ⅲ of Nomura Research Institute, Ltd.
April 1985	Joined Nomura Research Institute, Ltd.

Naoko Mikami

Date of birth:	March 12, 1961
Experience:	
March 2024-present	Non-executive Director of the Board, KURARAY CO., LTD.
March 2022-present	Non-executive Director of the Board, Earth Corporation
June 2021-present	Non-executive Director of the Board, SHOWA SANGYO CO., LTD.
January 2020	Executive Vice President and Representative Director of the Board in charge of Product Development Division of C'BON COSMETICS Co., Ltd. (retired in 2021)
June 2019	Representative Director and Vice President of C'BON COSMETICS Co., Ltd..
June 2017	Senior Executive Officer, Director of the Board, in charge of Administration Division of C'BON COSMETICS Co., Ltd..
June 2012	Director of the board, in charge of Production Dept of C'BON COSMETICS Co., Ltd.
June 2011	Executive Officer, in charge of Production Dept of C'BON COSMETICS Co., Ltd.
January 2010	Joined C'BON COSMETICS Co., Ltd.
April 2007	Visiting Professor, Faculty of Pharmaceutical Sciences, Musashino University (retired in 2018)
July 2005	Manager, Chemicals Department, Amino Acid Company Manager, Cosmetics Research Laboratory, Amino Science Research Laboratory, Amino Science Company of Ajinomoto Co.
April 1983	Joined Ajinomoto Co.

Supplementary Documents to the Consolidated Financial Statements for the Year Ended December 31, 2024

1. Summary of Consolidated Statement of Financial Position
2. Summary of Consolidated Statement of Profit or Loss, Indices, etc.
3. Revenue Details
4. Profit Details
5. Summary of Consolidated Statement of Cash Flows

KIRIN HOLDINGS COMPANY, LIMITED
February 14, 2025

1.SUMMARY OF CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(¥ billions)

	As of December 31, 2024, Actual	As of December 31, 2023, Actual	Increase (decrease)	Description of changes
Non-current assets	2,313.0	1,911.8	401.2	
Property, plant and equipment	674.0	592.9	81.1	Increase by FANCL step acquisition, etc.
Goodwill	501.5	390.6	110.9	Same as above.
Intangible assets	659.6	303.5	356.0	Same as above.
Equity-accounted investees	216.2	370.7	(154.5)	Decrease by FANCL step acquisition, etc.
Other	261.7	254.0	7.7	
Current assets	1,041.2	957.8	83.4	
Inventories	359.0	331.0	28.0	
Trade and other receivables	502.9	444.9	57.9	
Cash and cash equivalents	118.6	131.4	(12.8)	
Other	60.7	50.5	10.2	.
Total assets	3,354.2	2,869.6	484.6	
Equity	1,533.7	1,425.8	107.9	
Equity attributable to owners of the Company	1,181.5	1,132.6	48.9	
Non-controlling interests	352.2	293.3	58.9	Increase by FANCL step acquisition, etc.
Non-current liabilities	1,076.4	770.9	305.4	
Bonds and borrowings	779.6	555.7	223.9	Increase due to new borrowings, etc.
Other	296.8	215.2	81.6	Increase in deferred tax liability, etc.
Current liabilities	744.1	672.8	71.3	
Bonds and borrowings	78.0	100.7	(22.7)	
Trade and other payables	364.3	306.7	57.6	
Other	301.8	265.5	36.3	
Total liabilities	1,820.4	1,443.7	376.7	
Total equity and liabilities	3,354.2	2,869.6	484.6	

2.SUMMARY OF CONSOLIDATED STATEMENT OF PROFIT OR LOSS, INDICES, etc.

(1) Summary of Statement of Profit or Loss, Indices, etc.

(¥ billions)

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual	Increase (decrease)	
Revenue	2,338.4	2,134.4	204.0	9.6%
Gross profit	1,066.0	963.5	102.5	10.6%
Selling, general and administrative expenses	855.0	762.0	93.0	12.2%
Normalized operating profit	211.0	201.5	9.5	4.7%
Other operating income	16.1	28.8	(12.7)	(44.0%)
Other operating expenses	101.8	80.0	21.7	27.2%
Operating profit	125.3	150.3	(25.0)	(16.6%)
Finance income	14.6	9.0	5.6	61.5%
Finance costs	18.0	10.5	7.5	71.0%
Share of profit of equity-accounted investees	37.0	32.8	4.3	13.0%
Gain on sale of equity-accounted investees	—	15.5	(15.5)	—
Impairment loss on equity-accounted investees	19.3	—	19.3	—
Profit before tax	139.7	197.0	(57.3)	(29.1%)
Income tax expense	53.9	46.6	7.3	15.7%
Profit	85.8	150.4	(64.6)	(43.0%)
Owners of the Company	58.2	112.7	(54.5)	(48.3%)
Non-controlling interests	27.6	37.7	(10.1)	(26.9%)
ROIC	4.1%	8.0%		
Normalized EPS	¥172	¥177	(¥5)	(2.8%)
Revenue (excluding liquor tax)	2,051.5	1,854.9	196.6	10.6%
Normalized operating profit ratio (excluding liquor tax)	10.3%	10.9%		
ROE	5.0%	10.7%		
Normalized EBITDA	309.0	293.0	16.0	5.5%
Gross Debt Equity Ratio	0.73	0.58		

ROIC= Profit after tax before interest / (Average total interest-bearing liabilities at beginning and end of the period + Average total equity at beginning and end of the period)

Normalized EPS = Normalized profit / Average number of shares outstanding during period

Normalized profit = Profit attributable to Owners of the Company ± Other operating income and expenses and other items after income taxes

Normalized EBITDA = Normalized operating profit + Depreciation and amortization* + Dividends received from equity-accounted investees

* Depreciation and amortization exclude those from right-of-use assets.

(2) Exchange Rate for the Consolidation of Profit or Loss of the Major Overseas Companies

(¥)

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual
Lion (AUD)	100.15	93.64
Four Roses (USD)	152.24	141.20
Coke Northeast (USD)	152.24	141.20
Blackmores (AUD)	100.15	95.73

(3) Period for the Consolidation of Profit or Loss of the Major Overseas Company

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual
San Miguel Brewery	From October 2023 to September 2024	From October 2022 to September 2023

3. REVENUE DETAILS

(¥ billions)

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual	Increase (decrease)	
Revenue	2,338.4	2,134.4	204.0	9.6%
Alcoholic Beverages	1,081.7	1,045.1	36.6	3.5%
Kirin Brewery	662.7	648.1	14.6	2.3%
Lion	294.7	281.1	13.7	4.9%
Australia & NZ	203.0	198.8	4.2	2.1%
US Craft etc	91.7	82.3	9.5	11.5%
Four Roses	27.4	24.5	2.9	11.7%
Other and elimination	96.9	91.4	5.4	5.9%
Non-alcoholic Beverages	564.9	516.2	48.7	9.4%
Kirin Beverage	268.8	257.8	11.0	4.3%
Coke Northeast	286.9	250.1	36.8	14.7%
Other and elimination	9.2	8.2	0.9	11.4%
Pharmaceuticals	495.3	441.9	53.4	12.1%
Kyowa Kirin	495.6	442.2	53.3	12.1%
Elimination	(0.3)	(0.4)	0.1	—
Health Science	175.3	103.4	71.9	69.6%
FANCL	34.5	—	34.5	—
Blackmores	69.1	32.0	37.1	116.1%
Kyowa Hakko Bio	50.2	51.4	(1.3)	(2.4%)
Other and elimination	21.5	19.9	1.5	7.7%
Other	21.3	27.8	(6.6)	(23.6%)

(Reference) Revenue excluding liquor tax

(¥ billions)

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual
Kirin Brewery	402.3	392.2

4. PROFIT DETAILS

(1) Normalized Operating Profit Details

(¥ billions)

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual	Increase (decrease)	
Normalized operating profit	211.0	201.5	9.5	4.7%
Alcoholic Beverages	124.0	119.9	4.1	3.4%
Kirin Brewery	75.1	72.9	2.2	3.0%
Lion	31.4	32.4	(1.0)	(3.2%)
Australia & NZ	21.6	22.1	(0.5)	(2.2%)
US Craft etc.	9.8	10.3	(0.6)	(5.3%)
Four Roses	10.1	9.0	1.1	12.4%
Others	7.5	5.7	1.9	33.1%
Non-alcoholic Beverages	64.0	52.4	11.6	22.2%
Kirin Beverage	18.3	16.9	1.4	8.1%
Coke Northeast	44.3	33.9	10.4	30.7%
Others	1.4	1.5	(0.2)	(10.6%)
Pharmaceuticals	91.9	96.0	(4.1)	(4.3%)
Kyowa Kirin	91.9	96.0	(4.1)	(4.3%)
Health Science	(10.9)	(12.5)	1.6	—
FANCL	2.0	—	2.0	—
Blackmores	6.0	(0.5)	6.5	—
Kyowa Hakko Bio	(14.0)	(8.5)	(5.5)	—
Others	(4.9)	(3.6)	(1.4)	—
Other	0.0	(0.1)	0.1	—
Corporate expenses and inter-segment eliminations	(58.0)	(54.2)	(3.9)	—

Each normalized operating profit in each segment is calculated by adding back management fees paid to the Company to normalized operating profit.

(2) Other Operating Income and Other Operating Expenses

(¥ billions)

	Year ended December 31, 2024, Actual	Year ended December 31,2023, Actual	Increase (decrease)
Other operating income	16.1	28.8	(12.7)
Gain on sale of property, plant and equipment and intangible assets	3.7	6.1	(2.4)
Gain on sale of shares of subsidiaries	7.4	14.8	(7.5)
Other	5.1	7.9	(2.8)
Other operating expenses	101.8	80.0	21.7
Impairment losses	13.4	30.0	(16.6)
Business restructuring expenses	37.4	2.8	34.6
Loss on disposal and sale of property, plant and equipment and intangible assets	7.1	2.8	4.4
Loss on sale of shares of subsidiaries	—	19.4	(19.4)
Loss on step acquisitions	18.3	—	18.3
Other	25.6	25.2	0.4

(3) Finance Income, Finance Costs, Share of Profit of Equity-accounted Investees, etc.

(¥ billions)

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual	Increase (decrease)
Finance income	14.6	9.0	5.6
Interest income	10.4	3.5	6.9
Dividend income	0.7	0.6	0.1
Foreign exchange gains (net)	1.4	4.3	(2.9)
Other	2.1	0.6	1.5
Finance costs	18.0	10.5	7.5
Interest paid	6.9	5.9	1.0
Loss on valuation of financial instruments	10.2	3.9	6.2
Other	0.9	0.6	0.2
Share of profit of equity-accounted investees	37.0	32.8	4.3
San Miguel Brewery	31.0	30.3	0.6
Others	6.1	2.5	3.6
Gain on sale of equity-accounted investees	—	15.5	(15.5)
Impairment loss on equity-accounted investees	19.3	—	19.3

5. SUMMARY OF CONSOLIDATED STATEMENT OF CASH FLOWS

(1) Summary of Statement of Cash Flows

(¥ billions)

	Year ended December 31, 2024, Actual	Year ended December 31, 2023, Actual	Increase (decrease)
Cash flows from operating activities	242.8	203.2	39.6
Profit before tax	139.7	197.0	(57.3)
Depreciation and amortization	95.7	87.2	8.5
Other	7.4	(81.1)	88.5
Cash flows from investing activities	(329.4)	(226.1)	(103.3)
Acquisition of property, plant and equipment and intangible assets	(180.6)	(113.8)	(66.8)
Other	(148.8)	(112.3)	(36.5)
Cash flows from financing activities	58.1	35.9	22.2
Increase (decrease) in interest-bearing liabilities	200.8	126.2	74.6
Dividends paid	(72.7)	(71.2)	(1.5)
Other	(70.0)	(19.1)	(50.9)
Exchange rate changes.	15.6	4.8	10.8
Net increase (decrease) in cash and cash equivalents	(12.8)	17.9	(30.6)
Net increase (decrease) in cash and cash equivalents resulting from transfers to assets held for sale	—	25.5	(25.5)

(2) Information by Segment

As of December 31, 2024, Actual

(¥ billions)

	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science	Others	Adjustment	Total
Depreciation and amortization	29.1	11.5	20.6	7.5	0.9	5.8	75.4
Acquisition of property, plant and equipment and intangible assets	32.6	19.9	105.2	7.5	3.9	11.5	180.6
Normalized EBITDA	175.3	75.5	112.4	(2.8)	0.9	(52.2)	309.0

Depreciation and amortization exclude those from right-of-use assets.

As of December 31, 2023, Actual

(¥ billions)

	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science	Others	Adjustment	Total
Depreciation and amortization	28.0	11.4	17.2	4.6	0.9	5.4	67.6
Acquisition of property, plant and equipment and intangible assets	32.1	26.3	33.6	12.1	2.8	6.9	113.8
Normalized EBITDA	170.6	63.8	113.2	(6.6)	0.9	(48.8)	293.0

Depreciation and amortization exclude those from right-of-use assets.

Supplementary Documents to the Forecast Consolidated Business Results for the Year Ending December 31, 2025

1. Summary of Consolidated Statements of Profit or Loss, Indices, etc.
2. Revenue Details
3. Profit Details
4. Information by Segment

KIRIN HOLDINGS COMPANY, LIMITED
February 14, 2025

1. SUMMARY OF CONSOLIDATED STATEMENT OF PROFIT OR LOSS, INDICES, etc.

(1) Summary of Statement of Profit or Loss, Indices, etc.

(¥ billions)

	Year ending December 31, 2025, Forecast	Year ended December 31, 2024, Actual	Increase (decrease)	
Revenue	2,440.0	2,338.4	101.6	4.3%
Normalized operating profit	212.0	211.0	1.0	0.5%
Other operating income	10.1	16.1	(6.1)	(37.6%)
Other operating expenses	30.1	101.8	(71.7)	(70.5%)
Operating profit	192.0	125.3	66.7	53.2%
Finance income	8.0	14.6	(6.6)	(45.5%)
Finance costs	10.5	18.0	(7.5)	(41.6%)
Share of profit of equity-accounted investees	40.5	37.0	3.5	9.5%
Impairment loss on equity-accounted investees	—	19.3	(19.3)	—
Profit before tax	230.0	139.7	90.3	64.6%
Income tax expense	54.0	53.9	0.1	0.2%
Profit	176.0	85.8	90.2	105.1%
Owners of the Company	150.0	58.2	91.8	157.7%
Non-controlling interests	26.0	27.6	(1.6)	(5.8%)
ROIC	7.2%	4.1%		
Normalized EPS	—	¥172	—	—
EPS	¥185	¥72	¥113	157.7%
Revenue (excluding liquor tax)	2,159.0	2,051.5	107.5	5.2%
Normalized operating profit ratio (excluding liquor tax)	9.8%	10.3%		
ROE	12.5%	5.0%		
Normalized EBITDA	325.5	309.0	16.5	5.3%
Gross Debt Equity Ratio	0.80	0.73		

ROIC = Profit after tax before interest / (Average total interest-bearing liabilities at beginning and end of the period + Average total equity at beginning and end of the period)

Normalized EPS = Normalized profit*1 / Average number of shares outstanding during period

*1 The formula for calculating normalized EPS will be changed as follows:

Normalized profit = Profit attributable to Owners of the Company ± Other operating income and expenses and other items after income taxes +other adjustments (ownership percentage adjustment related to Kyowa Kirin, other tax adjustments)

Other operating income and expenses and other items after income taxes include gains and losses on sales of investments accounted for under the equity method.

The tax rate used for other after-tax operating income and expenses is simply the statutory tax rate in Japan applicable to the Company (30.6%).

(Reconciliation table) Other tax adjustments used in calculating normalized EPS

(¥ billions)

	Year ended December 31, 2024, Actual
Adjustment of ownership percentage related to Kyowa Kirin Co., Ltd.	(2.7)
Impairment loss on equity-accounted investees	19.3
Tax adjustment related to loss due to step acquisition of FANCL Corporation shares	5.6
Others	(0.7)
Total	21.5

Normalized EBITDA = Normalized operating profit + Depreciation and amortization*2 + Dividends received from equity-accounted investees

*2 Depreciation and amortization excludes that related to right-of-use assets.

(2) Exchange Rate for the Consolidation of Profit or Loss of the Major Overseas Companies

(¥)

	Year ending December 31, 2025, Forecast	Year ended December 31, 2024, Actual
Lion (AUD)	95.00	100.15
Four Roses Distillery (USD)	145.00	152.24
Coke Northeast (USD)	145.00	152.24
Blackmores (AUD)	95.00	100.15

(3) Period for the Consolidation of Profit or Loss of the Major Overseas Company

	Year ending December 31, 2025, Forecast	Year ended December 31, 2024, Actual
San Miguel Brewery	From October 2024 to September 2025	From October 2023 to September 2024

2. REVENUE DETAILS

(1) Revenue Details

(¥ billions)

	Year ending December 31, 2025, Forecast	Year ended December 31, 2024, Actual	Increase (decrease)	
Revenue	2,440.0	2,338.4	101.6	4.3%
Alcoholic Beverages	1,087.8	1,081.7	6.1	0.6%
Kirin Brewery	671.9	662.7	9.2	1.4%
Lion	293.1	294.7	(1.7)	(0.6%)
Australia & NZ	198.2	203.0	(4.8)	(2.4%)
US Craft etc.	94.9	91.7	3.1	3.4%
Four Roses Distillery	27.8	27.4	0.4	1.5%
Other and elimination	95.0	96.9	(1.8)	(1.9%)
Non-alcoholic Beverages	576.3	564.9	11.5	2.0%
Kirin Beverage	281.6	268.8	12.8	4.8%
Coke Northeast	285.0	286.9	(1.9)	(0.7%)
Other and elimination	9.7	9.2	0.5	5.8%
Pharmaceuticals	478.0	495.3	(17.3)	(3.5%)
Kyowa Kirin	478.0	495.6	(17.6)	(3.5%)
Elimination	—	(0.3)	0.3	—
Health Science	260.0	175.3	84.8	48.4%
FANCL	116.0	34.5	81.5	236.4%
Blackmores	70.5	69.1	1.4	2.0%
Kyowa Hakko Bio	51.0	50.2	0.8	1.5%
Other and elimination	22.5	21.5	1.1	5.1%
Other	37.9	21.3	16.6	78.0%

(Reference) Revenue excluding liquor tax

(¥ billions)

	Year ending December 31, 2025, Forecast	Year ended December 31, 2024, Actual
Kirin Brewery	418.8	402.3

3. PROFIT DETAILS

(1) Normalized Operating Profit Details

(¥ billions)

	Year ending December 31, 2025, Forecast	Year ended December 31, 2024, Actual	Increase (decrease)	
Normalized operating profit	212.0	211.0	1.0	0.5%
Alcoholic Beverages	130.3	124.0	6.3	5.1%
Kirin Brewery	84.0	75.1	8.9	11.9%
Lion	30.0	31.4	(1.4)	(4.3%)
Australia & NZ	19.4	21.6	(2.2)	(10.1%)
US Craft etc.	10.6	9.8	0.8	8.4%
Four Roses Distillery	10.2	10.1	0.1	0.6%
Others	6.2	7.5	(1.4)	(18.1%)
Non-alcoholic Beverages	64.9	64.0	1.0	1.5%
Kirin Beverage	20.0	18.3	1.7	9.6%
Coke Northeast	43.5	44.3	(0.8)	(1.8%)
Others	1.4	1.4	0.0	3.6%
Pharmaceuticals	79.0	91.9	(12.9)	(14.0%)
Kyowa Kirin	79.0	91.9	(12.9)	(14.0%)
Health Science	3.7	(10.9)	14.6	—
FANCL	9.3	2.0	7.3	366.5%
Blackmores	6.2	6.0	0.2	2.9%
Kyowa Hakko Bio	(6.5)	(14.0)	7.5	—
Others	(5.3)	(4.9)	(0.4)	—
Other	(2.3)	0.0	(2.4)	—
Corporate expenses and inter-segment eliminations	(63.6)	(58.0)	(5.6)	—

4. INFORMATION BY SEGMENT

Year ending December 31, 2025, Forecast

(¥ billions)

	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science	Others	Adjustment	Total
Depreciation and amortization	27.3	12.8	23.0	13.8	1.2	9.7	87.7
Acquisition of property, plant and equipment and intangible assets	52.1	23.8	84.6	9.8	8.8	8.3	187.4
Normalized EBITDA	157.6	77.7	102.0	17.5	24.6	(53.9)	325.5

Depreciation and amortization exclude those from right-of-use assets.

Year ended December 31, 2024, Actual

(¥ billions)

	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu-ticals	Health Science	Others	Adjustment	Total
Depreciation and amortization	29.1	11.5	20.6	7.5	0.9	5.8	75.4
Acquisition of property, plant and equipment and intangible assets	32.6	19.9	105.2	7.5	3.9	11.5	180.6
Normalized EBITDA	175.3	75.5	112.4	(2.8)	0.9	(52.2)	309.0

Depreciation and amortization exclude those from right-of-use assets.